Details for New Drug Application (NDA): 212462
✉ Email this page to a colleague
NDA 212462 describes ABIRATERONE ACETATE, which is a drug marketed by Amneal Pharms, Apotex, Dr Reddys, Florida, Glenmark Speclt, Hikma, MSN, Mylan, Novugen, Qilu, Rising, Teva Pharms Usa, and Wockhardt Bio Ag, and is included in fifteen NDAs. It is available from twenty-four suppliers. Additional details are available on the ABIRATERONE ACETATE profile page.
The generic ingredient in ABIRATERONE ACETATE is abiraterone acetate. There are twenty-five drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the abiraterone acetate profile page.
The generic ingredient in ABIRATERONE ACETATE is abiraterone acetate. There are twenty-five drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the abiraterone acetate profile page.
Summary for 212462
| Tradename: | ABIRATERONE ACETATE |
| Applicant: | Qilu |
| Ingredient: | abiraterone acetate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 212462
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ABIRATERONE ACETATE | abiraterone acetate | TABLET;ORAL | 212462 | ANDA | Apotex Corp. | 60505-4764 | 60505-4764-6 | 60 TABLET, FILM COATED in 1 BOTTLE (60505-4764-6) |
| ABIRATERONE ACETATE | abiraterone acetate | TABLET;ORAL | 212462 | ANDA | Florida Pharmaceutical Products, LLC. | 71921-178 | 71921-178-20 | 120 TABLET in 1 BOTTLE (71921-178-20) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 250MG | ||||
| Approval Date: | Sep 27, 2019 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 500MG | ||||
| Approval Date: | Jun 25, 2021 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
